BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

Core Viewpoint - BioAtla, Inc. is exploring strategic options to maximize shareholder value, including potential asset sales and partnerships, while implementing a significant restructuring plan to reduce operating expenses by approximately 70% [1][2]. Company Overview - BioAtla is a clinical-stage biotechnology company based in San Diego, focusing on Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [3]. - The company utilizes a proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting and reduced toxicity compared to traditional antibodies [3]. - BioAtla holds over 780 active patent matters, with more than 500 issued patents, covering methods of making and manufacturing CAB product candidates [3]. Clinical Pipeline - BioAtla's clinical pipeline includes several assets at various stages: - Ozuriftamab vedotin (CAB-ROR2-ADC) is in Phase 3 for treating oropharyngeal squamous cell carcinoma (OPSCC) and has potential applications in HPV+ cancers, representing a market opportunity of over $7 billion [8]. - Mecbotamab vedotin (CAB-AXL-ADC) is in Phase 2 for multiple solid tumor indications, including mKRAS NSCLC and soft tissue sarcoma [10]. - Evalstotug (CAB-CTLA-4) is in Phase 2, designed for safer combination therapies with anti-PD-1 agents [11]. - BA3182 (CAB-EpCAM x CAB-CD3) is in Phase 1 for advanced adenocarcinoma [7]. Strategic Actions - The company has engaged Tungsten Advisors as its exclusive strategic financial advisor to assist in evaluating potential transactions [2]. - The restructuring plan aims to retain essential employees while significantly reducing the workforce to enhance cost containment [1].